# US 2006/0154969 A1 · Adenosine receptor selective modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154969 A1
- Document ID: US20060154969A1
- Status: Published application
- Kind: A1
- Application number: 10/471,079
- Filed: 2002-02-28
- Published: 2006-07-13
- Earliest claimed: 2001-03-07
- Assignees: Bayer Schering Pharma Aktiengesellschaft
- Inventors: Ulrich Rosentreter; Thomas Kramer; Andrea Vaupel; Walter Hubsch; Nicole Diedrichs; Thomas Krahn; Klaus Dembowsky; Johannes-Peter Stasch
- Web page: https://patentgrep.com/patent/US20060154969A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- A61P 17/06: Antipsoriatics
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/85: in position 3
- C07D 401/14: containing three or more hetero rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the compounds of formula (I), to a method for producing the same and to the use thereof as medicaments.

## Claims

### Claim 1

A compound of the formula (I)
in which
R1, R2 and R3 independently of one another represent (C1-C8)-alkyl which may be substituted up to three times, independently of one another, by hydroxyl, (C1-C4)-alkoxy, (C3-C7)-cycloalkyl, (C2-C4)-alkenyl, (C2-C4)-alkynyl, halogen or (C6-C10)-aryloxy,
(C6-C10)-aryl which may be substituted up to three times, independently of one another, by halogen, nitro, (C1-C4)-alkoxy, carboxyl, (C1-C4)-alkoxy-carbonyl or mono- or di-(C1-C4)-alkylamino,
(C1-C8)-alkoxy which may be substituted by hydroxyl, (C1-C4)-alkoxy, (C3-C7)-cycloalkyl, (C2-C4)-alkenyl, (C6-C10)-aryl, 5- or 6-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and/or S, (C6-C10)-aryloxy, halogen, cyano, (C1-C4)-alkoxycarbonyl, amino or mono- or di-(C1-C4)-alkylamino,
hydrogen, hydroxyl, halogen, nitro, cyano, or —NH—C(O)—R7,
in which
R7 represents (C1-C4)-alkyl which may be substituted by hydroxyl or (C1-C4)-alkoxy, (C3-C7)-cycloalkyl or (C6-C10)-aryl which may be substituted up to three times, independently of one another, by halogen, nitro, (C1-C4)-alkoxy, carboxyl, (C1-C4)-alkoxycarbonyl or mono- or di-(C1-C4)-alkylamino,
or
R1 and R2 are attached to adjacent phenyl ring atoms and, together with the two ring carbon atoms, form a 5- to 7-membered saturated or partially unsaturated heterocycle having one or two heteroatoms from the group consisting of N, O and/or S which may be substituted by (C1-C4)-alkyl or oxo,
R4 represents (C1-C8)-alkyl which may be substituted by hydroxyl, —NH—CO—R8, (C1-C4)-alkoxy, (C3-C7)-cycloalkyl, (C6-C10)-aryl, 5- or 6-membered saturated or partially unsaturated heterocyclyl having up to three heteroatoms from the group consisting of N, O and/or S or 5- or 6-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and/or S, or (C3-C7)-cycloalkyl which may be substituted by hydroxyl or (C1-C8)-alkyl,
in which
R8 represents (C1-C8)-alkyl which may be substituted by hydroxyl or (C1-C4)-alkoxy, (C3-C7)-cycloalkyl or (C6-C10)-aryl which may be substituted up to three times, independently of one another, by halogen, nitro, (C1-C4)-alkoxy, carboxyl, (C1-C4)-alkoxycarbonyl or mono- or di-(C1-C4)-alkylamino,
R5 represents hydrogen or (C1-C4)-alkyl which may be substituted by hydroxyl, (C1-C4)-alkoxy or (C3-C7)-cycloalkyl,
or
R4 and R5 together with the nitrogen atom to which they are attached form a 5- to 7-membered saturated or partially unsaturated heterocycle which may contain one or two further heteroatoms from the group consisting of N, O and/or S in the ring and which may be mono- to trisubstituted, independently of one another, by oxo, fluorine, chlorine, bromine, hydroxyl, (C1-C6)-alkyl or (C1-C6)-alkoxy,
and
R6 represents (C3-C7)-cycloalkyl or (C1-C8)-alkyl, where alkyl may be substituted up to three times, independently of one another, by (C3-C7)-cyclo-alkyl, hydroxyl, —CO—NH—R9, (C1-C4)-alkoxy, (C2-C4)-alkenyl, (C6-C10)-aryl or 5- to 10-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and/or S,
where
aryl and heteroaryl for their part may be substituted by halogen, (C1-C4)-alkyl, (C1-C4)-alkoxy, amino, mono- or di-(C1-C4)-alkylamino, nitro, cyano or hydroxyl,
and
R9 represents hydrogen, (C1-C8)-alkyl which may be substituted by hydroxyl or (C1-C4)-alkoxy, (C3-C7)-cycloalkyl or (C6-C10)-aryl which may be substituted up to three times, independently of one another, by halogen, nitro, (C1-C4)-alkoxy, carboxyl, (C1-C4)-alkoxycarbonyl or mono- or di-(C1-C4)-alkylamino,
or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

### Claim 2

A compound of the formula (I)
in which
R1, R2 and R3 independently of one another represent hydrogen, hydroxyl, (C1-C4)-alkyl, trifluoromethyl, trifluoromethoxy, fluorine, chlorine, (C1-C4)-alkoxy which may be substituted by hydroxyl, (C1-C4)-alkoxy, (C2-C4)-alkenyl or (C3-C6)-cycloalkyl, —NH—C(O)—CH3 or —NH—C(O)—C2H5,
or
R1 and R2 are attached to adjacent phenyl ring atoms and represent a group —O—CH2—O— or —CH2—CH2—O—,
R4 represents (C1-C6)-alkyl which may be substituted by hydroxyl, (C1-C4)— alkoxy, (C3-C6)-cycloalkyl, —NH—C(O)—CH3, phenyl, furyl, pyridyl, imidazolyl, thienyl or hexahydropyranyl, or (C3-C6)-cycloalkyl,
R5 represents hydrogen or (C1-C4)-alkyl which may be substituted by hydroxyl, (C1-C4)-alkoxy or (C3-C6)-cycloalkyl,
or
R4 and R5 together with the nitrogen atom to which they are attached form a 5- to 7-membered saturated or partially unsaturated heterocycle which may contain a further heteroatom from the group consisting of N; O or S in the ring and which may be mono- to trisubstituted, independently of one another, by hydroxyl, (C1-C4)-alkyl or (C1-C4)-alkoxy,
and
R6 represents (C3-C6)-cycloalkyl, (C1-C6)-alkyl which may be substituted up to two times, independently of one another, by (C3-C6)-cycloalkyl, —CO—NH—R9, hydroxyl, (C1-C4)-alkoxy, (C2-C4)-alkenyl, phenyl or 5- or 6-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and/or S,
where
phenyl and heteroaryl for their part may be substituted by halogen, (C1-C4)-alkyl, (C1-C4)-alkoxy, amino, mono- or di-(C1-C4)-alkylamino, nitro, cyano or hydroxyl,
and
R9 represents hydrogen or (C1-C4)-alkyl,
or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

### Claim 3

A compound of the formula (I)
in which
R1 and R2 independently of one another represent hydrogen, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy or —NH—C(O)—CH3, where the alkoxy radicals for their part may be substituted by hydroxyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy or cyclopropyl,
or
R1 and R2 are attached to adjacent phenyl ring atoms and represent a group —O—CH2—O—,
R3 represents hydrogen,
R4 represents methyl, ethyl, n-propyl, isopropyl, where the alkyl radicals for their part may be substituted by hydroxyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, cyclopropyl, —NH—C(O)—CH3, furyl, pyridyl, imidazolyl or hexahydropyranyl, or cyclopropyl,
R5 represents hydrogen or methyl,
or
R4 and R5 together with the nitrogen atom to which they are attached represent pyrrolidinyl, morpholinyl, piperidinyl or 4-hydroxypiperidinyl
and
R6 represents methyl, ethyl or n-propyl, where the alkyl radicals for their part may be substituted up to two times, independently of one another, by hydroxyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, imidazolyl, nitrofuranyl, pyridyl, phenyl which for its part may in turn be substituted by cyano, nitro, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy or amino, —C(O)—NH2 or —C(O)—NH—CH3,
or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

### Claim 4 (depends on 1)

A process for preparing compounds of the formula (I) as defined in claim 1, characterized in that
compounds of the formula (II)
in which
R1, R2, R3, R4 and R5 are as defined in claim 1
are reacted with compounds of the formula (III)
R6—X (III)
in which
R6 is as defined in claim 1 and X represents a leaving group.

### Claim 5 (depends on 1)

A compound of the formula (I) as defined in claim 1 for the prophylaxis and/or treatment of disorders.

### Claim 6 (depends on 1)

A composition, comprising at least one compounds of the formula (I) as defined in claim 1 and at least one further auxiliary.

### Claim 7 (depends on 1)

The use of compounds of the formula (I) as defined in claim 1 for preparing medicaments for the prophylaxis and/or treatment of disorders of the cardiovascular system (cardiovascular disorders).

### Claim 8 (depends on 1)

The use of compounds of the formula (I) as defined in claim 1 for preparing medicaments for the prophylaxis and/or treatment of disorders of the urogenital system and cancer.

### Claim 9 (depends on 1)

The use of compounds of the formula (I) as defined in claim 1 for preparing medicaments for the prophylaxis and/or treatment of inflammatory and neuro-inflammatory disorders, neurodegenerative disorders and pain.

### Claim 10 (depends on 1)

The use of compounds of the formula (I) as defined in claim 1 for preparing medicaments for the prophylaxis and/or treatment of disorders of the respiratory tract, of liver fibrosis and liver cirrhosis and diabetes.
